Inhalation Anesthesia Market Size Share & Trends Analysis Report By Application (Induction, Maintenance), By Product (Sevoflurane, Isoflurane, Desflurane), By Region, And Segment Forecasts, 2019 - 2025

Industry Insights

The global inhalation anesthesia market size was valued at nearly USD 1.12 billion in 2018 and is expected to expand at a CAGR of 3.5% during the forecast period. The rapid rise in the aging population suffering from cancer, cardiovascular, spinal, orthopedic, respiratory, gastrointestinal, neurological, and other diseases and disorders is anticipated to drive the growth. The increasing number of orthopedic procedures such as ligament and other soft tissue repair procedures is also contributing to the growth of the daycare ambulatory surgeries, which is expected to boost usage of inhalation anesthesia. Furthermore, an increasing number of emergency cases and accidents is also expected to positively influence market growth over the forecast period.

Inhalational anesthesia (IA) becomes the anesthetic of choice over Intravenous Anesthesia (IVA) among the majority of healthcare practitioners, as it helps avoid excessive dosage and keeps the patient’s autonomic functions intact. These drugs are eliminated via the lungs and they have lower chances of accumulation in the body. Drugs administered through inhaled route have limited tolerance and addiction level compared to alternatives routes. IA has a lower risk of delirium and is cost-effective compared to IVA. Furthermore, a rising number of surgical procedures is one of the major driving factors. For instance, according to the annual estimates of Sedana Medical, there were about 4.5 to 7.5 million people ventilated and sedated worldwide in 2017. Such a large and ever-increasing number of people induced with IA is expected to significantly propel market growth.

The anesthesia recycling market is also expected to play a significant role in shaping the market dynamics and enhance the competition. The anesthesia recycling market is gaining significance owing to the environmental impact of inhalation anesthetics released into the atmosphere from the hospital environment. These anesthetic gases contribute up to 1.0% of global carbon dioxide emissions, leading to greater environmental damage. The major concern in using anesthetic gases is that patient use accounts for only 5.0% and the rest 95.0% is released into the atmosphere which contributes to global warming.

To address the environmental impact of anesthetic gases, new technologies are being developed to scavenge them from hospital vents and recycle them. The anesthesia recycling systems are being developed by 2 companies, Anesthesia reclamation LLC, and Deltasorb Technologies (Blue Zone Technology). Anesthesia reclamation LLC has developed the Anesthetic Recapture System, which is a cryogenic condensing system used to collect the waste anesthetics from the operating rooms.

Application Insights

On the basis of application, the inhalation anesthesia market is bifurcated into induction and maintenance. In 2018, the maintenance segment led the market with revenue of USD 984.6 million and is anticipated to grow at a lucrative CAGR over the forecast period. This is owing to its higher requirement of volume for maintenance and faster induction and recovery from anesthesia. On the other hand, the induction segment is anticipated to register the fastest CAGR of 4.9% over the forecast period.

Induction of anesthesia requires a higher concentration of drug as compared to the amount required for maintenance of anesthesia. Factors influencing induction of anesthesia include therapeutic index of drug, Minimum Alveolar Concentration (MAC), potency, patient’s age, rate of metabolism by kidney/liver, compatibility with other drugs, and blood/gas solubility. Inhalation general anesthetic agents have a different mechanism of action in the central nervous system depending on blood and gas solubility and Minimum Alveolar Concentration (MAC) concentration of different drugs. Hence, patients sensitive to anesthetic agents must be regularly monitored to avoid delays in anesthesia recovery.

Product Type Insights

On the basis of product, the market is classified into sevoflurane, isoflurane, and desflurane. These products are used for the induction and maintenance of anesthesia for patients during surgical products. Baxter Healthcare is the only player with all the 3 products in its portfolio. AbbVie Inc. has sevoflurane and isoflurane in its portfolio. Piramal Healthcare presently has sevoflurane and isoflurane in its portfolio and may capture a significant market share of Baxter in the years to come owing to new product launches.

Globally, sevoflurane is widely used for anesthesia induction owing to its therapeutic advantages and low cost. Sevoflurane led the market in 2018 with a revenue of USD 782.6 million and is anticipated to grow at a lucrative rate over the forecast period. Desflurane and isoflurane are used based on patient requirements and the need for prolonged induction or maintenance of anesthesia.

Isoflurane is used limitedly, owing to its longer induction time and patient recovery time compared to sevoflurane. However, isoflurane is expected to witness the fastest CAGR of over 6.5% over the forecast period, owing to the relative sparing effect on cardiovascular function. This makes it particularly useful in the anesthetic management of weak or geriatric patients.

Regional Insights

North America led the market in 2018 and is expected to grow at a lucrative rate over the forecast period, owing to the increasing prevalence of various chronic diseases and the presence of advanced healthcare facilities. The demand for surgical products which includes inpatient surgery and ambulatory surgery is the highest in North America and is a major growth driver for the regional market.

On the other hand, Asia Pacific is expected to expand at the fastest CAGR of 4.0% over the forecast period. Key factors contributing to its rapid growth include increasing population, public and private healthcare expenditure, availability of healthcare insurance for masses, and incidence of chronic diseases.

The rise in medical tourism coupled with rapid penetration of insurance coverage will enable more people to opt for surgical products and is expected to significantly boost the usage of inhalation anesthetics. Expansion of ambulatory healthcare centers is expected to cater to the growing population in Asia Pacific thus positively impacting the market.

Inhalation Anesthesia Market Share Insights

The market is led primarily by players such as Abbvie and In the next seven years, the market is expected to witness strong generic competition from players like Piramal Healthcare, Lunan Pharmaceuticals, and other regional players. Some of the key players operating in this market include Halocarbon Products Corporation; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country level and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, GVR has segmented the global inhalation anesthesia market report on the basis of product, application, and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Sevoflurane

  • Isoflurane

  • Desflurane

• Application Outlook (Revenue, USD Million, 2014 - 2025)

  • Induction

  • Maintenance

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Spain

    • France

    • Italy

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Singapore

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE